Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma
Abstract. The serum soluble CD163 (sCD163) is elevated in patients with inflammatory disease and several types of cancer. However, the prognostic value of serum sCD163 in pancreatic ductal adenocarcinoma (PDAC) has not yet been investigated. In this study, serum level of sCD163 was measured by using...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2020-09-01
|
| Series: | Journal of Pancreatology |
| Online Access: | http://journals.lww.com/10.1097/JP9.0000000000000055 |
| _version_ | 1819063476908195840 |
|---|---|
| author | Qinglin Fei, MD Yu Pan, MD, PhD Xingxing Yu, MD Ronggui Lin, MD, PhD Xianchao Lin, MD, PhD Heguagn Huang, MD |
| author_facet | Qinglin Fei, MD Yu Pan, MD, PhD Xingxing Yu, MD Ronggui Lin, MD, PhD Xianchao Lin, MD, PhD Heguagn Huang, MD |
| author_sort | Qinglin Fei, MD |
| collection | DOAJ |
| description | Abstract. The serum soluble CD163 (sCD163) is elevated in patients with inflammatory disease and several types of cancer. However, the prognostic value of serum sCD163 in pancreatic ductal adenocarcinoma (PDAC) has not yet been investigated. In this study, serum level of sCD163 was measured by using the peripheral blood of 54 patients with PDAC, 20 patients with benign tumor of pancreas, and 30 healthy volunteers (healthy controls). The association between serum sCD163 level and overall survival was analyzed. Receiver operating characteristic (ROC) curves were generated, and areas under the curve (AUC) were compared to evaluate the diagnostic accuracy, including CA 19-9, CEA, CA 125, CA 153, and serum sCD163 level. Serum sCD163 level of patients with PDAC was significantly higher than patients with benign tumor (P = .002) and health controls (P < .001). Using ROC curves, we found that the AUC values of serum sCD163 were higher than those of CA 125 and CA 153, but lower than those of CA 19-9 and CEA. Serum sCD163 was negatively correlated with lymphocyte to monocyte ratio (LMR; r = −0.428, P = .001). In addition, the prognosis of PDAC patients with sCD163 ≥ median was worse than sCD163 < median by using univariate analysis (P = .027). Further, multivariate analysis showed that higher level of serum sCD163 was still associated with poorer overall survival (P = .020). In conclusion, the serum sCD163 has the potential as a new promising parameter to predict the prognosis in PDAC patients. |
| first_indexed | 2024-12-21T15:15:17Z |
| format | Article |
| id | doaj.art-2ecbc558c0a541ee9bfffff77ba896b1 |
| institution | Directory Open Access Journal |
| issn | 2096-5664 2577-3577 |
| language | English |
| last_indexed | 2024-12-21T15:15:17Z |
| publishDate | 2020-09-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Journal of Pancreatology |
| spelling | doaj.art-2ecbc558c0a541ee9bfffff77ba896b12022-12-21T18:59:10ZengWolters Kluwer Health/LWWJournal of Pancreatology2096-56642577-35772020-09-013314715310.1097/JP9.0000000000000055202009000-00005Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinomaQinglin Fei, MD0Yu Pan, MD, PhD1Xingxing Yu, MD2Ronggui Lin, MD, PhD3Xianchao Lin, MD, PhD4Heguagn Huang, MD5Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China.Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China.Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China.Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China.Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China.Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China.Abstract. The serum soluble CD163 (sCD163) is elevated in patients with inflammatory disease and several types of cancer. However, the prognostic value of serum sCD163 in pancreatic ductal adenocarcinoma (PDAC) has not yet been investigated. In this study, serum level of sCD163 was measured by using the peripheral blood of 54 patients with PDAC, 20 patients with benign tumor of pancreas, and 30 healthy volunteers (healthy controls). The association between serum sCD163 level and overall survival was analyzed. Receiver operating characteristic (ROC) curves were generated, and areas under the curve (AUC) were compared to evaluate the diagnostic accuracy, including CA 19-9, CEA, CA 125, CA 153, and serum sCD163 level. Serum sCD163 level of patients with PDAC was significantly higher than patients with benign tumor (P = .002) and health controls (P < .001). Using ROC curves, we found that the AUC values of serum sCD163 were higher than those of CA 125 and CA 153, but lower than those of CA 19-9 and CEA. Serum sCD163 was negatively correlated with lymphocyte to monocyte ratio (LMR; r = −0.428, P = .001). In addition, the prognosis of PDAC patients with sCD163 ≥ median was worse than sCD163 < median by using univariate analysis (P = .027). Further, multivariate analysis showed that higher level of serum sCD163 was still associated with poorer overall survival (P = .020). In conclusion, the serum sCD163 has the potential as a new promising parameter to predict the prognosis in PDAC patients.http://journals.lww.com/10.1097/JP9.0000000000000055 |
| spellingShingle | Qinglin Fei, MD Yu Pan, MD, PhD Xingxing Yu, MD Ronggui Lin, MD, PhD Xianchao Lin, MD, PhD Heguagn Huang, MD Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma Journal of Pancreatology |
| title | Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma |
| title_full | Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma |
| title_fullStr | Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma |
| title_full_unstemmed | Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma |
| title_short | Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma |
| title_sort | serum biomarker cd163 predicts overall survival in patients with pancreatic ductal adenocarcinoma |
| url | http://journals.lww.com/10.1097/JP9.0000000000000055 |
| work_keys_str_mv | AT qinglinfeimd serumbiomarkercd163predictsoverallsurvivalinpatientswithpancreaticductaladenocarcinoma AT yupanmdphd serumbiomarkercd163predictsoverallsurvivalinpatientswithpancreaticductaladenocarcinoma AT xingxingyumd serumbiomarkercd163predictsoverallsurvivalinpatientswithpancreaticductaladenocarcinoma AT rongguilinmdphd serumbiomarkercd163predictsoverallsurvivalinpatientswithpancreaticductaladenocarcinoma AT xianchaolinmdphd serumbiomarkercd163predictsoverallsurvivalinpatientswithpancreaticductaladenocarcinoma AT heguagnhuangmd serumbiomarkercd163predictsoverallsurvivalinpatientswithpancreaticductaladenocarcinoma |